New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
08:08 EDTWXWuXi PharmaTech begins operation of new high-potency API laboratory
WuXi PharmaTech's manufacturing subsidiary, Syn-The-All Pharmaceutical Co., has begun operation of a high-potency active pharmaceutical ingredient laboratory in Shanghai, thereby adding HPAPI processing to its portfolio of services. The lab will support process development and clinical-trial supply of high-potency small molecules at kilogram scale.
News For WX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
19:20 EDTWXWuXi consortium to acquire Ambrx
A consortium consisting of entities affiliated with Fosun Pharmaceutical, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech (WX) announced that it has signed a merger agreement to acquire Ambrx (AMBX). The transaction is expected to close in Q2. Chairman Chen Qiyu of Fosun Pharma said, "This joint acquisition will result in great synergy with [our] current R&D system and platform. Under the help of Fosun Pharma, Ambrx's business expanding in China will enable Chinese patients to get faster access to innovative therapeutic drugs." Ge Li, CEO of Wuxi, remarked, "This transaction will allow WuXi to broadly access Ambrx's best-in-class ADC platform and biologics development capabilities."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use